Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atenolol + esmolol + metoprolol
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of three cardioselective beta-1 adrenergic receptor blockers. Each component works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. They prevent the action of naturally occurring substances like epinephrine and norepinephrine.
- Brand names
- Brevibloc
02
Targets
ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on atenolol + esmolol + metoprolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atenolol + esmolol + metoprolol.